ANI Pharmaceuticals, Inc. has acquired ANDAs for 23 previously marketed generic drug products from IDT Australia, Ltd. (“IDT”) for $2.6 million and a limited single-digit royalty for one product.    Additionally, ANI acquired active pharmaceutical ingredient for one of the acquired products for $135 thousand. In 2015, ANI had secured the U.S. licensing rights and 40% to 50% of the net profits upon commercialization for these products from IDT for $1.0 million. This acquisitio...